Clinical Trials Logo

ß-thalassemia Major clinical trials

View clinical trials related to ß-thalassemia Major.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01745120 Completed - ß-thalassemia Major Clinical Trials

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized, open label, multi-site, single-dose, phase 1/2 study in up to 18 participants (including at least 3 adolescents between 12 and 17 years of age, inclusive) with β-thalassemia major. The study will evaluate the safety and efficacy of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product [autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene].

NCT ID: NCT00390858 Completed - Clinical trials for Transfusional Iron Overload

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Start date: September 2003
Phase: Phase 2
Study type: Interventional

In this 4-year extension study the safety, efficacy and and pharmacokinetics of deferasirox in regularly transfused pediatric patients with β-thalassemia major was assessed. Patients who successfully completed the main 1 year trial (NCT00390858) were eligible to continue in this extension trial and receive chelation therapy with deferasirox for up to 4 years.